Promoted Content Promoted Content

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual BoothOffering a portfolio of products & services including APIs, CMO services, generics, biosimilars & differentiated formulations.

            Contact the Supplier

            Lead Product(s): Denileukin Diftitox,Anti-PD-1 agent

            Therapeutic Area: Oncology Product Name: E7777

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Eisai

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 09, 2020

            Details:

            Combination of E7777 with an anti-PD-1 agent provided clear benefit both in terms of tumor growth control, and a highly significant improvement in overall survival.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): LNP3794,BI 1701963

            Therapeutic Area: Oncology Product Name: BI 3011441

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Boehringer Ingelheim GmbH

            Deal Size: $50.0 million Upfront Cash: Undisclosed

            Deal Type: Collaboration May 27, 2021

            Details:

            Lupin’s proprietary MEK inhibitor compound is planned for clinical development in combination with Boehringer Ingelheim’s KRAS inhibitor pipeline to address KRAS-driven cancers.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): XL102

            Therapeutic Area: Oncology Product Name: XL102

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Exelixis

            Deal Size: $29.5 million Upfront Cash: $10.0 million

            Deal Type: Licensing Agreement December 07, 2020

            Details:

            Exelixis has exercised exclusive option for Aurigene’s novel CDK7 inhibitor under the companies’ July 2019 agreement. Exelixis has now assumed responsibility for the future clinical development, commercialization, and global manufacturing of the compound now known as XL102.